147920-22-7

Usage

Chemical compound

2''-amino-2''-deoxyarbekacin

Classification

Aminoglycoside antibiotic

Derived from

Arbekacin

Modification

At the 2'' position of the amino group

Enhanced properties

Improved antibacterial activity and pharmacokinetics

Effectiveness

Potent and effective against various bacterial infections, including multidrug-resistant strains

Mechanism of action

Inhibits protein synthesis in bacteria

Clinical use

Treatment of serious infections where other antibiotics have failed

Demonstrated effectiveness

Shown in clinical trials

Overall assessment

Promising antibiotic with potent antibacterial properties; potential for managing complicated infections.

Upstream product

• 161906-84-9 4'',6''-O-benzylidene-1,3''-bis(N-benzyloxycarbonyl)-3,2',6'-tris(N-tert-butoxycarbonyl)-2''-(tert-butoxycarbonyl)amino-2''-deoxydibekacin 
• 161909-28-0 C₅₆H₇₅N₅O₁₈ 
• 161972-20-9 2''-amino-4'',6''-O-benzylidene-1,3''-bis(N-benzyloxycarbonyl)-3,2',6'-tris(N-tert-butoxycarbonyl)-2''-deoxydibekacin 
• 161906-83-8 4'',6''-O-benzylidene-1,3''-bis(N-benzyloxycarbonyl)-3,2',6'-tris(N-tert-butoxycarbonyl)dibekacin 
• 161909-27-9 1,3''-bis(N-benzyloxycarbonyl)-3,2',6'-tris(N-tert-butoxycarbonyl)dibekacin 
• 161906-85-0 4'',6''-O-benzylidene-3,2',6'-tris(N-tert-butoxycarbonyl)-2''-(tert-butoxycarbonyl)amino-2''-deoxydibekacin 

Downstream Products

• 161822-09-9 3,2',6',3'',4'''-pentakis(N-tert-butoxycarbonyl)-2''-(tert-butoxycarbonyl)amino-2''-deoxyarbekacin 

Relevant academic research and scientific papers

Dibekacin derivatives and arbekacin derivatives active against resistant bacteria

As new dibekacin derivatives and new arbekacin derivatives are now provided 2"-amino-2"-deoxydibekacin, 2"-amino-5,2"-dideoxydibekacin, 2"-amino-2"-deoxyarbekacin, 2"-amino-5,2"-dideoxyarbekacin, 2"-amino-5,2"-dideoxy-5-epi-fluoroarbekacin and 2"-amino-5,2"-dideoxy-5-epi-aminoarbekacin which all exhibit high antibacterial activity against a wide variety of gram-positive and gram-negative bacteria, including resistant bacteria such as methicillin-resistant Staphylococcus aureus and which are of low toxicity to mammals and are useful as antibacterial agent for treatment of bacterial infections.

Synthesis of 2'-amino-2'-deoxyarbekacin and its analogs having potent activity against methicillin-resistant Staphylococcus aureus

Based on our studies on the enzymatic modifications of arbekacin by methicillin-resistant Staphylococcus aureus (MRSA), replacement of the 2'-hydroxyl group by an amino group in arbekacin was designed to synthesize derivatives that would be active against